Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: The purpose of this study was to evaluate the impact of adjunctive rifampicin therapy on the outcomes of prosthesis retention versus removal in patients with staphylococcal prosthetic joint infection (PJI) undergoing antibacterial treatment.

Methods: A retrospective study was conducted on 227 patients diagnosed with Staphylococcal PJI from March 2014 to September 2023 who underwent debridement, antibiotics, and implant retention (DAIR) or explantation and revision surgery. Based on antimicrobial susceptibility testing, we used an effective baseline antibiotic regimen. We defined the combination of this regimen with rifampicin as the "rifampicin treatment group" and the regimen without rifampicin as the "non-rifampicin treatment group".

Results: A total of 79 patients were included in the rifampin treatment group and 148 in the non-rifampin treatment group. There was no significant difference in the remission rate of PJI between the rifampin treatment group and the non-rifampin treatment group (79.75% vs 73.65%, p = 0.083). Additionally, Kaplan-Meier survival curve analysis showed no statistically significant difference between the two groups (p = 0.509). However, the incidence of drug-related adverse events was significantly higher in the rifampin treatment group compared to the non-rifampin treatment group (31.65% vs 8.78%, p < 0.001). There were no significant difference in treatment success rates between the use and non-use of rifampin in DAIR, one-stage revision, or two-stage revision, as well as in hip or knee joints. Binary logistic regression analysis identified diabetes and active smoking as independent significant risk factors for treatment failure, while rifampin was not an independent risk factor affecting the outcome.

Conclusion: The study has not demonstrated that the standard antibiotic regimen combined with rifampin has a significant effect on the efficacy of retaining or removing prostheses in staphylococcal PJI, but rather increases drug-related adverse events. Standard surgical procedures, accurate pathogen diagnosis, and treatment are particularly crucial in the management of PJI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307336PMC
http://dx.doi.org/10.3389/fcimb.2025.1587436DOI Listing

Publication Analysis

Top Keywords

treatment group
24
rifampin treatment
12
non-rifampin treatment
12
treatment
11
rifampin efficacy
8
implant retention
8
joint infection
8
staphylococcal pji
8
antibiotic regimen
8
regimen rifampicin
8

Similar Publications

Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.

Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.

View Article and Find Full Text PDF

Impact of Albumin-Binding Moieties on Structure-Affinity-Pharmacokinetic Relationships of Novel FAP-Targeting Radioligands.

Mol Pharm

September 2025

Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-Ku, Kyoto 606-8501, Japan.

Fibroblast activation protein (FAP) is an attractive biomarker for tumor-targeting radioligands. While [Ga]Ga-FAPI-46 is a promising FAP-targeting radioligand for cancer diagnosis, clinical application of [Lu]Lu-FAPI-46 for targeted radionuclide therapy is limited due to its insufficient tumor retention. Albumin binder (ALB) including 4-(-iodophenyl)butyric acid is widely utilized to improve tumor accumulation of radioligands.

View Article and Find Full Text PDF

Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy.

Clin J Am Soc Nephrol

September 2025

Kidney Division, Peking University First Hospital, Peking University Institute of Nephrology; Key Laboratory of Kidney Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, China.

Background: The Therapeutic Effects of Steroids in IgA Nephropathy Global (TESTING) trial demonstrated that glucocorticoid therapy reduced proteinuria and improved kidney outcomes in patients with Immunoglobulin A Nephropathy (IgAN). Galactose-deficient IgA1 (Gd-IgA1) plays a central role in IgAN pathogenesis by promoting immune complex formation. However, the effects of glucocorticoid on pathogenic IgA levels remain unclear.

View Article and Find Full Text PDF

Background: The benefits of rehabilitation in acute ischemic stroke patients following thrombectomy remain underexplored. We assessed which activities of daily living (ADLs) show the greatest improvement after goal-directed therapy in an inpatient rehabilitation setting.

Methods: We retrospectively analyzed pre- and post-rehabilitation functional assessments in 40 acute ischemic stroke patients treated with mechanical thrombectomy.

View Article and Find Full Text PDF

Background: The loss of a loved one is a common yet stressful event in later life. Internet- and mobile-based interventions have been proposed as an effective treatment approach for individuals with prolonged grief.

Objective: The AgE-health study aimed to investigate the efficacy of an eHealth intervention, trauer@ktiv, in reducing prolonged grief symptoms in a sample of older adults.

View Article and Find Full Text PDF